In-Stent Restenosis and a Drug-Coated Balloon: Insights from a Clinical Therapeutic Strategy on Coronary Artery Diseases

Cardiology Research and Practice - Tập 2020 - Trang 1-7 - 2020
Dai‐Min Zhang1, Shao‐Liang Chen1
1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China

Tóm tắt

Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery. However, 10%–20% restenosis is still an important complication that restricts the clinical safety and efficacy of drug-eluting stents. In-stent restenosis may lead to the recurrence of major cardiovascular adverse events, including angina pectoris, acute myocardial infarction, and even sudden cardiac death. These events are currently serious problems that occur after coronary stent implantation. Clinical physicians face a difficult choice for in-stent restenosis treatment. Recent studies indicate that a drug-coated balloon has promising clinical efficacy similar to the drug-eluting stents for treating coronary in-stent restenosis. Therefore, in this study, we highlight the progress of coronary intervention and the use of drug-coated balloons in the treatment of in-stent restenosis (ISR).

Từ khóa


Tài liệu tham khảo

10.1038/nrcardio.2013.13

P. Scacciatella, 2013, Effects of EPC capture stent and CD34+ mobilization in acute myocardial infarction, Minerva Cardioangiol, 61, 211

10.1016/s0735-1097(88)80046-9

10.1055/s-0031-1278368

10.1016/j.jacc.2011.10.909

M. S. Lee, 2008, Clinical presentation of patients with in-stent restenosis in the drug-eluting stent era, The Journal of Invasive Cardiology, 20, 401

B. Schnorr, 2011, Review of clinical data with Paccocath- coated balloon catheters, Minerva Cardioangiologica, 59, 431

10.1016/j.jacc.2013.12.036

10.1016/j.jacc.2010.07.028

10.1161/01.cir.100.18.1872

10.1016/j.jacc.2015.06.1301

10.1016/j.amjcard.2015.11.042

10.1016/j.iccl.2015.12.006

10.1002/mabi.201000509

10.1161/01.cir.0000018168.15904.bb

10.1161/01.cir.0000069943.41206.bd

10.1093/eurheartj/ehv205

10.1016/j.jacc.2011.01.011

10.1016/j.jcin.2012.08.005

10.1002/ccd.27359

10.1016/j.medengphy.2010.10.009

10.1016/s0041-1345(03)00211-2

10.4161/cbt.2.3.360

10.1128/mmbr.69.1.79-100.2005

10.1634/theoncologist.2010-0196

10.1002/ccd.26957

10.1111/joic.12333

10.1007/s40119-016-0064-4

10.4244/eijy14m08_12

10.1056/nejmoa061254

10.1007/s00392-008-0682-5

10.1016/j.jcin.2012.01.008

10.1161/circulationaha.108.839282

10.1016/s0140-6736(12)61964-3

10.1016/j.jacc.2012.01.015

10.1016/j.jcin.2013.08.011

10.4244/eijv10i5a102

10.1016/j.jcin.2010.10.012

10.1016/j.jacc.2012.07.040

10.4244/eijv7i6a113

10.1016/j.carrev.2012.06.002

10.1016/j.jcin.2017.11.032

10.1093/eurheartj/ehu278

10.23736/S0026-4725.18.04641-8

D. Cafasso, 2012, How paclitaxel can improve results in diabetics, Journal of Cardiovascular Surgery, 53, 13

10.2147/VHRM.S28979

10.1161/jaha.118.011245

10.1016/j.jacc.2019.12.051

10.1016/j.jacc.2019.11.065

10.1016/j.jacc.2019.12.046

10.1002/ccd.26546